

Product Specification Sheet

**p73β (p73β) Antibody**

<b>Cat.</b> P73B13-S	Rabbit Anti-Human p73β Antiserum #1	<b>SIZE:</b> 100 ul
<b>Cat.</b> P73B13-A	Rabbit Anti-Human p73β Ig G # 1 (affinity pure)	<b>SIZE:</b> 100 ug
<b>Cat.</b> P73B13-P	Human p73β Control peptide # 1	<b>SIZE:</b> 100 ug

Human **p73α** is the first known structural and functional homolog of one of the most studied tumor protein, p53 (1). Human p73 gene encodes two distinct polypeptides: The p73 long form (human 636 AA, termed p73α; mouse 590 aa) and the short form (499 AA; termed p73β). The short form arises through alternative splicing of the p73. With the exception of C-terminal 5 AA, p73β is identical to p73α. Both p73α and p73β transcripts were detected all human tissues. The endogenous p73α protein has also been detected in cell extracts of HT-29, IMR-32, and SK-N-SH cells. Other cell lines, SK-N-MC SK-N-AS displayed significantly reduced levels of p73α protein (1). The C-terminal domain (364-393) of p53 and p73 are quite distinct. p73 has been mapped to human chromosome 1p36, a region that is frequently deleted in a variety of human cancers including neuroblastoma, colon cancer, melanoma, and breast cancer.

**Source of Antigen and Antibodies**

and antibodies generated in **rabbits**. The control peptide has been used to affinity purify the antibodies.

<b>Antigen</b>	An 8 amino acid peptide sequence (gene accession # BAB87245.1) ( <b>designated p73B13-P, control peptide</b> ) mapping at the C-terminus of human p73β (1) was used to generate anti-human p73β. The peptide was coupled with KLH (carrier protein)
<b>Ab Host/type</b>	Rabbit, Polyclonal antiserum # <b>p73B13-S</b> and IgG, purified over antigen-agarose (Cat # <b>p73B13-A</b> )
<b>2-Ab</b>	Cat # 20320, goat anti-rabbit IgG-HRP (AP, biotin, FITC conjugates also available).
<b>-ve control IgG</b>	Cat # 20009-1, Rabbit (non-immune) Serum IgG, purified, suitable for ELISA, Western, IHC as -ve control

**Form & Storage of Antibodies/Peptide Control**

**Antiserum (unpurified)**  
100ul solution lyophilized powder  
Supplied 0.05% azide, **Reconstitute** powder in 100 ul PBS

**Affinity pure IgG**  
100 ug/100ul solution lyophilized powder  
Supplied in **Buffer:** PBS+0.1% BSA  
**Reconstitute powder** in PBS at 1mg/ml

**Control/blocking peptide**  
100 ug/100 ul solution lyophilized powder  
Supplied in **Buffer:** PBS pH 7.5,  
**Reconstitute powder in PBS at 1 mg/ml.**

**Storage**  
**Short-term:** unopened, undiluted liquid vials at -200C and powder at 4oC or -20oC..

**Long-term:** at -20C or below in suitable aliquots after reconstitution. Do not freeze and thaw and store working, diluted solutions.

**Stability:** 6-12 months at -20oC or below.  
**Shipping:** 4oC for solutions and room temp for powder

**Recommended Usage**

**Western Blotting** (1:1K-5K for neat serum and 1-10 ug/ml for affinity pure using Chemiluminescence technique) (1). Although, p73β transcripts has been detected in various cell lines, it is not know if p73β protein can also detected and distinguished from p73α.

**ELISA** (1:10K-1:100K; using 50-100 ng of control peptide/well).

**Specificity & Cross-reactivity**

The 8 AA human P73B13-P immunogenic peptide sequence has no significant homology with p73α. It is conserved in monkey p73. Antibody crossreactivity in various species is not established. Control peptide, because of its low mol. Wt (<3 kDa), is not suitable for Western. It should be used for ELISA or antibody blocking experiments (use 5-10 ug control peptide per 1 ug of aff pure IgG or 1 ul antiserum) to confirm antibody specificity (see detailed protocol see detailed protocol at the web site).

**General References:** Kaghad, M et al (1997) Cell 90, 809-819; 2. Oren, M (1997) Cell 90, 829-832; Herranz M et al (1999) Cancer Res. 59, 2068-2071; Yang A et al (2000) Nature 404, 99-103

\*This product is for in vitro research use only.

**Related material available from ADI**

Anti-p53, Phosphorylated, acetylated, p63, p73

P73b13-S-A-P 100317A